MetaCap

BioMarin Pharmaceutical Inc. (BMRN)

NASDAQ: BMRNHealth CareBiotechnology: Pharmaceutical PreparationsUSD

60.41-1.01 (-1.64%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BMRN stock chart

Technical analysis

Key statistics

All statistics
Market cap
$11.70B
EPS (TTM)
-$0.10
52-week range
49.26 – 70.98
Day range
59.84 – 62.00
Volume / Avg
6.06M / 2.35M
Beta
—

52-week range

$49.26$70.98

BMRN stock today

On Nov 20, BMRN ended the session at $60.41, shedding $1.01 (1.64%), versus the S&P 500's 3.70% decline. Volume was 2.6x the average at 6.06M shares, a sign of unusually heavy trading. Shares are 14.9% below their 52-week high of $70.98, set on Aug 12, 2026 and 22.6% above the 52-week low of $49.26, in the middle of the past year's range.

BMRN is up 1.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 10.5%. BioMarin Pharmaceutical has posted a net loss over the last twelve months (EPS of -$0.10), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About BioMarin Pharmaceutical

Company profile

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Alexander Hardy
Headquarters
San Rafael, CA
Employees
3,221
IPO year
1999

Financial highlights

Full financials

In fiscal 2025, BioMarin Pharmaceutical generated $3.22 billion in revenue, up 12.9% from fiscal 2024, its 4th consecutive year of revenue growth. Net income was $348.9 million (-18.3% year over year), for a net margin of 10.8% versus a median of 6.9% in the prior 5 years. Gross margin was 77.7% (down from 79.7%) and operating margin 12.7%.

BioMarin Pharmaceutical annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$3.22B$2.85B$2.42B$2.10B$1.85B
Growth+12.87%+17.97%+15.42%+13.53%-0.76%
Net income$348.90M$426.86M$167.65M$141.56M$-64.08M
EPS (diluted)$1.80$2.21$0.87$0.75$-0.35

Analyst forecast

Forecast

Consensus (28 analysts)

buy

Avg. price target

$90.30+49.48%

  • Strong buy 5
  • Buy 16
  • Hold 7
  • Sell 0
  • Strong sell 0

Target range

Low $60.00High $120.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 2, 2026
EPS actual vs est.
$-0.08 vs $-0.30
Surprise
+73.33%

BMRN news

All BMRN news

BioMarin Pharmaceutical peers

Health Care sector
BMRN peer companies
CompanyPrice% ChgMarket capCompare
RDYDr. Reddy's Laboratories Ltd14.89+0.40%$12.41Bvs BMRN
ELANElanco Animal Health Incorporated25.74-2.09%$12.87Bvs BMRN
TGTXTG Therapeutics Inc.63.34-2.37%$9.57Bvs BMRN
JAZZJazz Pharmaceuticals plc230.26-2.62%$14.78Bvs BMRN
BBIOBridgeBio Pharma Inc.76.03-2.75%$14.81Bvs BMRN
SYRESpyre Therapeutics Inc.93.47-4.26%$8.88Bvs BMRN
MDGLMadrigal Pharmaceuticals Inc.379.10-4.45%$8.81Bvs BMRN
PRAXPraxis Precision Medicines Inc.300.43-3.37%$8.40Bvs BMRN

Indexes, lists and sector

BioMarin Pharmaceutical stock FAQ

What is BioMarin Pharmaceutical's stock price today?

BMRN last traded at $60.41 as of Nov 20, 4:00 PM EST, down 1.64% on the day. Prices are delayed at least 15 minutes.

Who is BioMarin Pharmaceutical's CEO?

Mr. Alexander Hardy is the chief executive officer of BioMarin Pharmaceutical Inc., which has about 3,221 employees.

What is the BMRN 52-week high?

The 52-week high for BMRN is $70.98 and the 52-week low is $49.26. The stock is currently 14.9% below its high.

Compare BMRN